Oral Anticoagulation Therapy (eBook)

Katie Kiser, Pharm.D., BCACP received her Bachelor of Science in Biology from King University in Bristol, Tennessee and her Doctor of Pharmacy from the University of North Carolina School of Pharmacy in Chapel Hill, North Carolina.  She completed her postgraduate year-one residency with emphasis in ambulatory care at Moses Cone Health System in Greensboro, North Carolina and her postgraduate year-tworesidency in ambulatory care at the University of North Carolina Hospitals in Chapel Hill, North Carolina.  Dr. Kiser is faculty at South College School of Pharmacy in Knoxville, Tennessee and previously taught at the University of Maryland School of Pharmacy in Baltimore, Maryland. Dr. Kiser has over 10 years of clinical and teaching experience in anticoagulation management and is a Board of Pharmaceutical Specialties certified Ambulatory Care Pharmacist.    Dr. Kiser has practiced primarily in the outpatient clinical setting and served as the Director of the UHC Antithrombosis Clinic in Baltimore, Maryland from 2010 – 2014.  Her current clinical practice is at NHC HealthCare in Farragut, Tennessee where she serves as a consultant pharmacist and specializes in oral anticoagulant management in a diverse rehabilitation and long term care population.  Dr. Kiser is an Associate Editor and co-founder of iForumRx.org which is an interactive web-based community designed to inform ambulatory care clinicians about high-quality, practice-changing evidence.   Dr. Kiser is highly involved with the American College of Clinical Pharmacy and has served in local and national leadership positions  She has written chapters in a leading pharmacy textbook and has participated in clinical research and written many peer-reviewed articles on anticoagulation, health literacy, the scholarship of teaching, and other topics. 

Table of Contents Part I Introduction 1 Part II Atrial Fibrillation 2: CHA2DS2VASc and HAS-BLED risk stratification tools 3: Male with priority of ischemic stroke reduction 4: Choosing an anticoagulant in an elderly patient 5: Patient with prior history of gastrointestinal hemorrhage 6: Patients with a history of intracranial hemorrhage 7: Concerns with anticoagulant adherence 8: Oral Anticoagulants in stable moderate Chronic Kidney Disease 9: Oral Anticoagulants in severe renal dysfunction 10: Oral Anticoagulants in patients with variable renal function 11: Patient with concomitant stable Coronary Artery Disease 12: Patient with concomitant acute venous thromboembolism 13: Patient with concomitant Mitral Valve Stenosis 14: Patient with concomitant Aortic Valve Stenosis Part III Warfarin management 15: Best practices for switching from stable warfarin 16: Patient-centered strategies for improving warfarin management Part IV Venous Thromboembolism (VTE) 17: Provoked versus unprovoked VTE 18: VTE prophylaxis in hip and knee replacement surgery 19: VTE prophylaxis in the intensive care unit 20: VTE and recent drug eluting stent placement 21: Acute VTE in a patient with moderate chronic kidney disease 22: Oral anticoagulation and duration in recurrent VTE 23: Pulmonary embolism (PE) with thrombolytic therapy Part V Acute Coronary Syndrome (ACS) 24: Patient on oral anticoagulant presenting with ACS 25: Oral anticoagulant therapy post-percutaneous coronary intervention 26: ST-segment elevation myocardial infarction (lytic candidate) on oral anticoagulant 27: ACS with bypass surgery Part VI Drug Interactions 28: Anticoagulant drug-drug interactions with CYP 3A4 inhibitors 29: Significance of P-glycoprotein (P-gp) drug-drug interactions 30: Considerations with pharmacodynamics drug-drug interactions 31: Management of direct oral anticoagulants with mixed P-gp/3A4 drug-drug interactions 32: Pharmacokinetic drug-drug interactions with warfarin Part VII Special Populations 33: Chronic Pain Management with anticoagulation 34: Anticoagulation management in atrial fibrillation catheter ablation 35: Anticoagulation management considerations for mechanical valves 36: Management of antiphospholipid antibody syndrome (APS) 37: VTE and Pregnancy 38: VTE in active Malignancy 39: Anticoagulation management in patients undergoing gastric bypass procedures 40: Patient presenting with minor bleeding 41: Patient presenting with major, life-threatening bleeding 42: Overdose of dabigatran